Showing results (181-190 of 220) with videos related to
Sort By:
Pageof 22
American Journal of Clinical Dermatology|October 8, 2024
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 StudyLaurent Mortier, Lisa Villabona, Ben Lawrence, et al.Journal for Immunotherapy of Cancer|March 30, 2021
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, et al.Expert Opinion on Drug Safety|May 25, 2017
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studiesDaniel Castellano, José Pablo Maroto, Enrique Espinosa, et al.Autoimmunity|August 16, 2011
Inflammatory profiles in severe pneumonia associated with the pandemic influenza A/H1N1 virus isolated in Mexico CityJoaquín Zúñiga, Martha Torres, Javier Romo, et al.The Lancet. Oncology|March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety studyJames Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.The Oncologist|April 25, 2020
Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective StudyJaime Feliu, Beatriz Jiménez-Munárriz, Laura Basterretxea, et al.Oncotarget|March 9, 2018
Molecular characterization of breast cancer cell response to metabolic drugsLucía Trilla-Fuertes, Angelo Gámez-Pozo, Jorge M Arevalillo, et al.European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysisChristian U Blank, James Larkin, Ana M Arance, et al.The Oncologist|July 14, 2017
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker AnalysisMiguel Martín, José I Chacón, Antonio Antón, et al.Cytokine|February 26, 2013
Seasonal and pandemic influenza H1N1 viruses induce differential expression of SOCS-1 and RIG-I genes and cytokine/chemokine production in macrophagesGustavo Ramírez-Martínez, Alfredo Cruz-Lagunas, Luis Jiménez-Alvarez, et al.Pageof 22